Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.78 -2.26%

-$0.42 today

Market cap
$1.98B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.41M

Average 1.23M

IMNM Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Immunome, Inc.NASDAQ: IMNM

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents falls 21.9% from a year ago

Cash & equivalents stood at $212.84M at the end of Q3 FY2026, down 21.9% from a year earlier and down 2.2% from the prior quarter. Over 3 fiscal years it compounded at +218.0% a year.

Context

  • Cash & equivalents amounted to 42.1% of total assets at the end of Q3 FY2026, down 49.0 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -21.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$212.84M-2.2% QoQ
Last fiscal yearDec 2025
$653.48M+355.9% YoY
Year agoSep 2025
$272.64M-21.9% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.9%——
1 year+355.9%——
3-year CAGR+218.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
653.48M USD
Year-over-year change
+355.9%
4-year CAGR
+90.9%

Cash & Equivalents vs competitors

How IMNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -21.9% is the 7th highest of 11, against a peer median of +9.6%.
  • Cash & equivalents amounts to 42.1% of total assets for IMNM, versus a peer median of 36.4%.
IMNM Competitors
Cash & Equivalents for IMNM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BCYCBicycle Therapeutics plcMar 2026$559.47M USD-29.4%+22.8%85.8%
IMCRImmunocore Holdings plcMar 2026$452.68M USD-5.1%+5.1%42.2%
IMTXImmatics N.V.Mar 2026€301.65M EUR+24.2%+32.5%55.5%
IMNMImmunome, Inc.Sep 2026$212.84M USD-21.9%+218.0%42.1%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$134.71M USD+203.3%+61.3%95.5%
IMMXImmix Biopharma, Inc.Mar 2026$79.25M USD+397.8%+91.2%82.7%
STROSutro Biopharma, Inc.Mar 2026$73.68M USD-30.6%+7.1%30.4%
MGNXMacroGenics, Inc.Mar 2026$66.52M USD-54.3%-19.3%30.5%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$62.1M USD+24.5%-34.7%17.8%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$40.1M USD+702.2%-29.7%15.8%
CLDXCelldex Therapeutics, Inc.Sep 2026$26.95M USD-25.2%-0.6%3.7%
Peer median (excluding IMNM) —+9.6%+6.1%36.4%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents49.23M20.32M98.68M143.35M653.48M
Short-term Investments0039.46M73.95M0
Net Receivables4.31M847K289K00
Inventory00000
Other Current Assets004.99M4.04M7.3M
Total Current Assets56.64M22.65M144.7M221.34M660.78M
Property, Plant & Equipment (Net)855K965K3.64M14.39M17.61M
Goodwill00000
Intangible Assets00000
Long-term Investments100K0100K0210K
Tax Assets00000
Other Non-current Assets332K432K100K4.51M4.59M
Total Non-current Assets1.29M1.4M3.84M18.9M22.41M
Total Assets57.93M24.05M148.54M240.24M683.19M
Account Payables3.08M2.4M3.31M14.19M3.34M
Short-term Debt00000
Tax Payables00000
Deferred Revenue0010.49M6.94M0
Other Current Liabilities2.02M1.96M4.98M8M15.15M
Total Current Liabilities9.73M7.33M21.83M54.31M44.99M
Long-term Debt00003.86M
Deferred Tax Liabilities00(5.49M)00
Deferred Revenue (Non-current)005.49M00
Other Non-current Liabilities12K05.49M00
Total Non-current Liabilities12K62K6.83M4.77M3.86M
Total Liabilities9.74M7.39M28.66M59.08M48.85M
Common Stock1K1K4K6K11K
Retained Earnings(79.11M)(116M)(222.81M)(515.77M)(728.16M)
Accumulated OCI(57.93M)022K57K0
Other Stockholders Equity00000
Minority Interest00000
Total Equity48.19M16.65M119.88M181.17M634.34M
Total Debt317K291K1.65M4.83M3.86M
Net Debt(48.91M)(20.03M)(97.03M)(138.52M)(649.63M)

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$16.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.